Your browser doesn't support javascript.
loading
Anti-VEGFR2-labeled enzyme-immobilized metal-organic frameworks for tumor vasculature targeted catalytic therapy.
Zhou, Jingrong; Wang, Kai; Ding, Shuaishuai; Zeng, Lijuan; Miao, Jingya; Cao, Yuhua; Zhang, Xiao; Tian, Gan; Bian, Xiu-Wu.
Affiliation
  • Zhou J; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China.
  • Wang K; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China.
  • Ding S; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China.
  • Zeng L; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China.
  • Miao J; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China.
  • Cao Y; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China.
  • Zhang X; International Joint Research Center for Precision Biotherapy, and Department of Stem Cell and Regenerative Medicine, The First Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, PR China.
  • Tian G; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China. Electronic address: tiangan09@163.com.
  • Bian XW; Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital, and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Third Military Medical University (Army Medical University), Chongqing 40038, PR China. Electronic address: bianxiuwu@263.net.
Acta Biomater ; 141: 364-373, 2022 03 15.
Article in En | MEDLINE | ID: mdl-35063709
ABSTRACT
Tumor vasculature-targeting therapy either using angiogenesis inhibitors or vascular disrupting agents offers an important new avenue for cancer therapy. In this work, a tumor-specific catalytic nanomedicine for enhanced tumor ablation accompanied with tumor vasculature disruption and angiogenesis inhibition was developed through a cascade reaction with enzyme glucose oxidase (GOD) modified on Fe-based metal organic framework (Fe-MOF) coupled with anti-VEGFR2.The GOD enzyme could catalyze the intratumoral glucose decomposition to trigger tumor starvation and yet provide abundant hydrogen peroxide as the substrate for Fenton-like reaction catalyzed by Fe-MOF to produce sufficient highly toxic hydroxyl radicals for enhanced chemodynamic therapy and instantly attacked tumor vascular endothelial cells to destroy the existing vasculature, while the anti-VEGFR2 antibody guided the nanohybrids to target blood vessels and block the VEGF-VEGFR2 connection to prevent angiogenesis. Both in vitro and in vivo results demonstrated the smart nanohybrids could cause the tumor cell apoptosis and vasculature disruption, and exhibited enhanced tumor regression in A549 xenograft tumor-bearing mice model. This study suggested that synergistic targeting tumor growth and its vasculature network would be more promising for curing solid tumors. STATEMENT OF

SIGNIFICANCE:

Cooperative destruction of tumor cells and tumor vasculature offers a potential avenue for cancer therapy. Under this premise, a tumor-specific catalytic nanomedicine for enhanced tumor ablation accompanied with tumor vasculature disruption and new angiogenesis inhibition was developed through a cascade reaction with glucose oxidase modified on the surface of iron-based metal organic framework coupled with VEGFR2 antibody. The resulting data demonstrated that a therapeutic regimen targeting tumor growth as well as its vasculature with both existing vasculature disruption and neovasculature inhibition would be more potential for complete eradication of tumors.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Metal-Organic Frameworks / Neoplasms Limits: Animals / Humans Language: En Journal: Acta Biomater Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Metal-Organic Frameworks / Neoplasms Limits: Animals / Humans Language: En Journal: Acta Biomater Year: 2022 Document type: Article